FDA Expands Afrezza to Pediatric Diabetes - Top_Thought_Leaders - MDSpire

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

By
Kathryn Wighton
May 29, 2026
3 min

Conexiant

Share

Top Thought Leaders in Gastroenterology

Brief introduction explaining scope and methodology.

Original Source(s)

Conexiant

FDA Expands Afrezza to Pediatric Diabetes

by Kathryn Wighton
May 29, 2026

Related Content

Frontiers In Surgery

Laparoscopic intracavitary catheterization combined with bleomycin quadruple sclerotherapy for retroperitoneal lymphatic malformations: a single-center case series

by Guanghua Zhang, Ming Sun, Hongxi Guo, Kai Zheng, Yu Chen, Hongqiang Bian, Haibin Wang, Jun Yang
May 29, 2026

Frontiers In Pediatrics

Restraint care in the pediatric intensive care unit: a qualitative investigation of nurses’ perspectives and experiences

by Xiaowen Dai, Qingqing Liu, Shuyi Ma, Li Wei
May 29, 2026

Conexiant

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

by Kathryn Wighton
May 27, 2026
6 min